Daily Cardiology Research Analysis
Analyzed 373 papers and selected 3 impactful papers.
Summary
Across cardiology this week, a large meta-analysis of randomized trials identifies prasugrel as offering the best efficacy–safety balance among P2Y12 inhibitors after PCI, while remote ischemic preconditioning significantly reduces contrast-associated acute kidney injury during coronary angiographic procedures. In translational science, a first-in-human NEJM study of stem-cell–derived engineered heart muscle allografts shows early signals of remuscularization and functional improvement in advanced heart failure.
Research Themes
- Antiplatelet therapy optimization after PCI
- Renal protection strategies during coronary angiography/PCI
- Regenerative therapies using engineered heart muscle in heart failure
Selected Articles
1. Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
In a network meta-analysis of 15 RCTs (48,904 patients), prasugrel reduced MACE versus clopidogrel, primarily by lowering myocardial infarction and stent thrombosis, and also outperformed ticagrelor on MACE. Ticagrelor did not reduce MACE versus clopidogrel and increased major bleeding, particularly intracranial hemorrhage.
Impact: This synthesis provides decisive comparative evidence to guide P2Y12 inhibitor selection after PCI, favoring prasugrel for ischemic benefit with acceptable bleeding risk.
Clinical Implications: For most PCI patients without contraindications (e.g., prior stroke/TIA), prasugrel may be preferred over ticagrelor or clopidogrel; ticagrelor’s intracranial bleeding signal warrants caution in high-risk patients. Individualize therapy based on ischemic and bleeding risk.
Key Findings
- Prasugrel vs clopidogrel: lower MACE (OR 0.80), MI (OR 0.71), and stent thrombosis (OR 0.48).
- Ticagrelor vs clopidogrel: no MACE reduction; lower stent thrombosis but higher major bleeding (OR 1.24) and intracranial hemorrhage (OR 1.89).
- Prasugrel vs ticagrelor: lower MACE (OR 0.83), MI (OR 0.78), and stent thrombosis (OR 0.66).
Methodological Strengths
- PRISMA-compliant systematic review and mixed-treatment meta-analysis of RCTs
- Large aggregate sample (48,904) enabling robust comparative estimates
Limitations
- Indirect comparisons inherent to network meta-analysis
- Heterogeneity in trial populations, bleeding definitions, and follow-up durations
Future Directions: Head-to-head randomized trials in contemporary PCI populations, including older adults and those with prior stroke/TIA, and analyses by clinical presentation and bleeding-risk strata.
IMPORTANCE: The relative efficacy and safety of oral P2Y purinergic receptor 12 (P2Y12) inhibitors (clopidogrel, ticagrelor, or prasugrel) after percutaneous coronary intervention (PCI) are not well defined. OBJECTIVE: To assess the efficacy and safety of oral P2Y12 inhibitors in patients who underwent PCI. DATA SOURCES AND STUDY SELECTION: PubMed and Embase were searched until November 15, 2025, for randomized clinical trials comparing at least 2 of the 3 agents. DATA EXTRACTION AND SYNTHESIS: Data were abstracted by 2 independent authors according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. Random-effects odds ratios (ORs) and 95% confidence intervals were calculated. Data were analyzed in December 2025. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was major adverse cardiovascular events (MACE), while the primary safety outcome was major bleeding. The primary analysis compared prasugrel and ticagrelor in reference to clopidogrel using a mixed treatment comparison meta-analysis. RESULTS: Data were analyzed from 15 randomized clinical trials that included 48 904 patients (mean [SD] age, 63.2 [4.21] years; 13 330 female patients [27.3%]). Compared with clopidogrel, there was a lower risk of MACE (OR, 0.80; 95% CI, 0.69-0.93) driven by lower myocardial infarction (OR, 0.71; 95% CI, 0.62-0.82) and stent thrombosis (OR, 0.48; 95% CI, 0.37-0.62) with prasugrel. MACE was not reduced with ticagrelor compared with clopidogrel, although there was lower stent thrombosis (OR, 0.73; 95% CI, 0.59-0.91). Furthermore, there was lower risk of MACE with prasugrel compared to ticagrelor (OR, 0.83; 95% CI, 0.70-0.98) driven by lower myocardial infarction (OR, 0.78; 95% CI, 0.65-0.94) and stent thrombosis (OR, 0.66; 95% CI, 0.49-0.88). There was a higher risk of major bleeding with ticagrelor vs clopidogrel (OR, 1.24; 95% CI, 1.01-1.52) driven by higher intracranial hemorrhage (OR, 1.89; 95% CI, 1.08-3.33). Prasugrel ranked first, followed by ticagrelor and clopidogrel, for MACE, myocardial infarction, and stent thrombosis. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis of 15 randomized clinical trials in patients who underwent PCI, prasugrel provided the optimal balance between efficacy and safety compared with ticagrelor and clopidogrel.
2. Remote Ischemic Preconditioning for Prevention of Contrast-Associated Acute Kidney Injury following Coronary Angiography or Percutaneous Coronary Intervention.
Across 36 RCTs (10,923 patients), remote ischemic preconditioning halved the risk of contrast-associated AKI and likely reduced in-hospital MACE during coronary angiography/PCI, without clear effects on dialysis or mortality. Overall certainty of evidence for AKI reduction was high.
Impact: Provides strong trial-level evidence for a low-cost, scalable intervention to prevent a frequent iatrogenic complication of cardiac catheterization.
Clinical Implications: Consider implementing remote ischemic preconditioning protocols before coronary angiography/PCI, especially in high-risk patients for AKI; integration with hydration and contrast-minimization strategies may further reduce risk.
Key Findings
- RIPC reduced contrast-associated AKI (RR 0.54; 95% CI 0.45–0.65; high-certainty evidence).
- RIPC probably reduced in-hospital MACE (RR 0.51; 95% CI 0.26–0.98; moderate certainty).
- No significant differences were observed for dialysis, in-hospital mortality, 30-day mortality, or 30-day MACE.
Methodological Strengths
- Comprehensive RCT synthesis with Cochrane RoB 2.0 and GRADE assessment
- Random-effects pooling and predefined kidney and cardiovascular outcomes
Limitations
- Heterogeneity in RIPC protocols and peri-procedural care across trials
- Limited power for mortality and dialysis endpoints; many single-center studies
Future Directions: Pragmatic implementation trials to validate real-world effectiveness, standardized RIPC protocols, and subgroup analyses in very high-risk patients.
BACKGROUND: Remote ischemic preconditioning may prevent contrast-associated acute kidney injury (AKI) and have cardioprotective effects in patients undergoing coronary angiographic procedures; however, results have been inconsistent. The aim of this systematic review and meta-analysis was to evaluate whether remote ischemic preconditioning lowers the risk of contrast-associated AKI and improves short-term kidney and cardiac outcomes in patients undergoing coronary angiography or percutaneous coronary intervention (PCI). METHODS: We performed a comprehensive literature search using PubMed, Embase, and the Cochrane Central Register of Controlled Trials from inception through December 6, 2025. Randomized controlled trials (RCTs) comparing remote ischemic preconditioning with either sham remote ischemic preconditioning or usual care for kidney and/or cardiac outcomes in patients undergoing coronary angiography or PCI were included. Two independent reviewers screened studies, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2.0 tool. Outcomes studied were contrast-associated AKI, need for dialysis, in-hospital mortality, in-hospital major adverse cardiovascular events (MACE), 30-day mortality, 30-day MACE, and major adverse kidney events at 30 days (MAKE30). Data were pooled using a random-effects model and expressed as risk ratios with 95% confidence intervals. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. RESULTS: Of the 5532 records identified, 36 RCTs encompassing 10,923 patients were included in this systematic review. Compared to sham remote ischemic preconditioning or usual care, remote ischemic preconditioning significantly reduced contrast-associated AKI (RR 0.54, 95% CI: 0.45-0.65; 30 RCTs, 5078 participants; high-certainty evidence). Remote ischemic preconditioning probably reduces in-hospital MACE (RR 0.51, 95% CI: 0.26-0.98; 4 RCTs, 1266 participants; moderate-certainty evidence). There were no differences in the need for dialysis, in-hospital mortality, 30-day mortality and 30-day MACE. CONCLUSIONS: Remote ischemic preconditioning reduces the risk of contrast-associated AKI and in-hospital MACE in patients undergoing coronary angiography or PCI, supporting its use as a simple adjunctive preventive strategy in clinical practice.
3. Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.
In an open-label phase 1–2 study of 20 patients with HFrEF, transplantation of engineered heart muscle allografts increased target-wall thickness by 4.5 mm at 3 months and modestly improved LVEF and health status, with adverse events in all patients. Longer-term follow-up is needed to assess safety and durability.
Impact: This first-in-human engineered heart muscle allograft study demonstrates structural remuscularization with functional and health-status gains, representing a potentially transformative regenerative approach for advanced heart failure.
Clinical Implications: Not ready for routine care; if safety and efficacy are confirmed in larger controlled trials with longer follow-up, engineered heart muscle could complement or delay device therapy and transplantation in selected HFrEF patients.
Key Findings
- Target-wall thickness increased by 4.5 mm at 3 months (P<0.001) following BioVAT transplantation.
- LVEF improved by 3.9 percentage points and KCCQ-OSS increased by 6.7 points at 3 months.
- Adverse events occurred in all patients; 3 deaths were reported, and immunosuppression posed challenges.
Methodological Strengths
- Prospective clinical investigation with prespecified structural, functional, and patient-reported endpoints
- Dose-escalation to a safe maximal dose with imaging-based assessments
Limitations
- Open-label, small sample size, and interim 3-month follow-up
- All patients received immunosuppression; adverse events were frequent
Future Directions: Randomized controlled trials with longer follow-up, optimization of graft dose and immunosuppression, mechanistic imaging of engraftment and integration, and hard clinical endpoints.
BACKGROUND: Biologic ventricular assist tissue (BioVAT) is formulated from engineered heart muscle composed of cardiomyocytes and stromal cells derived from allogeneic induced pluripotent stem cells for cardiac remuscularization in patients with heart failure and a reduced left ventricular ejection fraction. METHODS: We conducted an open-label, phase 1-2 study of tissue-engineered heart repair by means of BioVAT transplantation. Patients with heart failure and a left ventricular ejection fraction of 35% or less and at least one hypokinetic or dyskinetic left ventricular segment were treated with BioVAT allografts, which consisted of 5, 10, or 20 engineered-heart-muscle units. All the patients received immunosuppression. Safety was assessed as adverse events related to the procedure. The primary efficacy end points were the change from baseline in the target heart-wall thickness, the left ventricular ejection fraction, and the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score (KCCQ-OSS). RESULTS: A total of 20 patients were treated in the study. Three patients died during the study (1 each from vasoplegia, coronavirus disease 2019, and aortic dissection). One patient underwent heart transplantation. Immunosuppression was discontinued in 4 patients because of implantation of a left ventricular assist device (in 2 patients), renal failure (in 1 patient), and urothelial carcinoma (in 1 patient). Of the 16 patients who were treated with the safe maximal dose (20 engineered-heart-muscle units), 12 patients completed the prespecified 3-month interim follow-up. The least-squares mean increase in the target-wall thickness was 4.5 mm (90% confidence interval [CI], 3.7 to 5.4; P<0.001), the increase in the left ventricular ejection fraction was 3.9 percentage points (90% CI, 0.9 to 6.8; P = 0.04), and the increase in the KCCQ-OSS was 6.7 points (90% CI, 1.0 to 12.5; P = 0.06). All the patients had at least one adverse event. CONCLUSIONS: In this interim analysis, cardiac remuscularization with BioVAT was associated with an increase in the target heart-wall thickness, left ventricular ejection fraction, and KCCQ-OSS at 3 months; all the patients had at least one adverse event. Longer-term follow-up and further clinical investigation are warranted. (Funded by the German Center for Cardiovascular Research and Repairon; BioVAT-HF ClinicalTrials.gov number, NCT04396899.).